Quick Answer
Sonoma Pharmaceuticals, Inc. reported R&D Expense of $1.81 million for fiscal year 2025.
Sonoma Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.81M | -3.0% |
| 2024 | $1.87M | +803.9% |
| 2023 | $207.0K | +65.6% |
| 2022 | $125.0K | -77.5% |
| 2021 | $555.0K | -58.6% |
| 2020 | $1.34M | -11.8% |
| 2019 | $1.52M | -3.6% |
| 2018 | $1.57M | -0.1% |
| 2017 | $1.58M | -12.7% |
| 2016 | $1.81M | +17.8% |
| 2015 | $1.53M | -46.9% |
| 2014 | $2.89M | +29.9% |
| 2013 | $2.22M | +12.2% |
| 2012 | $1.98M | -3.2% |
| 2011 | $2.05M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $557.0K | +30.4% | -3.1% |
| September 30, 2025 | $575.0K | +13.6% | -3.2% |
| June 30, 2025 | $594.0K | +26.4% | +39.1% |
| December 31, 2024 | $427.0K | -29.0% | -15.6% |
| September 30, 2024 | $506.0K | -5.6% | +7.7% |
| June 30, 2024 | $470.0K | +44.6% | -21.8% |
| December 31, 2023 | $601.0K | — | +12.1% |
| September 30, 2023 | $536.0K | +168.0% | +64.9% |
- Sonoma Pharmaceuticals, Inc. showed a decrease of -3.0% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Sonoma Pharmaceuticals, Inc.’s r&d expense has declined by 11.3% (from $2.05 million to $1.81 million).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: